N/A
N=375
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
Dyslipidemia
Bottom Line
View on ClinicalTrials.gov: NCT00673660 ↗Enrolled (actual)
375
Serious AEs
0.0%
Results posted
Nov 2010
Primary outcome: Primary: Percentage of Participants Who Were Compliant With Statin Treatment — 86.7 Percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Patient Compliance (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Primary completion
- Oct 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Who Were Compliant With Statin Treatment |
86.7 | — |
| SECONDARY Available Lipid Profiles of Compliant and Non-compliant Participants |
178.94; 231.59; 101.61; 156.48; 50.70; 53.33 | <0.001 sig |
| SECONDARY Number of Participants With Reasons of Compliance to Statin Treatment |
— | — |
| SECONDARY Number of Participants With Reasons of Non-compliance to Statin Treatment |
11; 8; 7; 9; 5; 1 | — |
Summary
The purpose of the study is to show the compliance rates of the patients to statin treatment and the reasons of non-compliance.
Eligibility Criteria
Inclusion Criteria
- Patients diagnosed with dyslipidemia and taking or planning to take statin treatment.
- Patients living in the same city of the study center. o Patients aged 18 years and over.
Exclusion Criteria
- Patients with severe systemic disease
- Patients with alcohol and drug addiction and/or mental disease
- Patients nursing or pregnant, or planning to get pregnant during the study
Data sourced from ClinicalTrials.gov (NCT00673660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.